Free tool
Drug Trial Radar: Rare and genetic disease
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
14
Active, not recruiting, industry sponsors, Rare and genetic disease, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed102
14 trials
Showing 1 to 14, recently updated first.
- A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry DiseasePivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT05206773 · 122 participants · Start Mar 11, 2022 · Primary completion Dec 17, 2025
Drug: Venglustat (GZ402671); Placebo · For: Fabry Disease
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 50 sites in all
- A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)Pivotal-lookingActive, not recruiting
JCR Pharmaceuticals Co., Ltd.Industry
NCT04573023 · 86 participants · Start Feb 14, 2022 · Primary completion Oct 31, 2027
Drug: JR-141; Idursulfase and 1 more · For: Mucopolysaccharidosis II
Sites: Phoenix, Arizona; Oakland, California; Chicago, Illinois · 26 sites in all
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 GangliosidosisPivotal-lookingActive, not recruiting
Azafaros B.V.Industry
NCT07082543 · 75 participants (planned) · Start Jun 30, 2025 · Primary completion Feb 6, 2028
Drug: AZ-3102; Placebo · For: Gangliosidoses, GM2; Gangliosidosis, GM1
Sites: Oakland, California; Minneapolis, Minnesota; Rochester, Minnesota · 27 sites in all
- A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type IIPivotal-lookingActive, not recruiting
AO GENERIUMIndustry
NCT05208281 · 32 participants (planned) · Start Nov 30, 2021 · Primary completion Dec 20, 2027
Drug: GNR-055 1.0-2.0-3.0 mg/kg; GNR-055 2.0 mg/kg and 1 more · For: Mucopolysaccharidosis Type II; Metabolic Diseases
Sites: Moscow, Russia; Saint Petersburg, Russia; Simferopol, Russia · 5 sites in all
- ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPDPivotal-lookingActive, not recruiting
Amicus TherapeuticsIndustry
NCT03911505 · 21 participants · Start Feb 13, 2020 · Primary completion Mar 2027
Drug: Cipaglucosidase Alfa; Miglustat · For: Pompe Disease (Late-onset)
Sites: Gainesville, Florida; Jacksonville, Florida; Atlanta, Georgia · 17 sites in all
- A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)Pivotal-lookingActive, not recruiting
Denali Therapeutics Inc.Industry
NCT05371613 · 65 participants · Start Jul 21, 2022 · Primary completion Dec 2027
Drug: tividenofusp alfa; idursulfase · For: Mucopolysaccharidosis II
Sites: Oakland, California; Chicago, Illinois; Hackensack, New Jersey · 30 sites in all
- An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type IIPivotal-lookingActive, not recruiting
JCR Pharmaceuticals Co., Ltd.Industry
NCT04348136 · 27 participants · Start Sep 1, 2019 · Primary completion Mar 31, 2030
Drug: JR-141 · For: Mucopolysaccharidosis II
Sites: Fukui, Japan; Fukuoka, Japan; Gifu, Japan · 20 sites in all
- Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With PhenylketonuriaPivotal-lookingActive, not recruiting
BioMarin PharmaceuticalBioMarin (BMRN)
NCT05270837 · 55 participants · Start Jun 17, 2022 · Primary completion Jan 14, 2025
Drug: Pegvaliase · For: Phenylketonuria (PKU)
Sites: Phoenix, Arizona; Little Rock, Arkansas; Aurora, Colorado · 16 sites in all
- Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3Pivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT05222906 · 43 participants · Start Apr 18, 2022 · Primary completion Oct 2, 2025
Drug: Venglustat; imiglucerase · For: Gaucher's Disease Type III
Sites: New Haven, Connecticut; Iowa City, Iowa; Dallas, Texas · 22 sites in all
- A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal DiseasePivotal-lookingActive, not recruiting
Amicus TherapeuticsIndustry
NCT04020055 · 14 participants (planned) · Start Oct 31, 2022 · Primary completion Dec 31, 2026
Drug: migalastat HCl 150 mg · For: Fabry Disease
Sites: Atlanta, Georgia; Cleveland, Ohio; Fairfax, Virginia · 12 sites in all
- A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry DiseasePivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT05280548 · 104 participants · Start May 3, 2022 · Primary completion May 22, 2026
Drug: Venglustat (GZ402671); Agalsidase alfa and 2 more · For: Fabry Disease
Sites: Birmingham, Alabama; Los Angeles, California; Atlanta, Georgia · 54 sites in all
- Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)Pivotal-lookingActive, not recruiting
Napo Pharmaceuticals, Inc.Industry
NCT06721871 · 6 participants · Start May 1, 2025 · Primary completion Dec 2026
Drug: Crofelemer Powder for Oral Solution; Placebo Powder for Oral Solution · For: Microvillus Inclusion Disease; Congenital Disorders; Rare Diseases
Sites: Boston, Massachusetts; Rome, Italy; Dubai, United Arab Emirates
- Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase AlfaPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT04910776 · 17 participants · Start Sep 1, 2021 · Primary completion Mar 2, 2026
Drug: avalglucosidase alfa · For: Glycogen Storage Disease Type II
Sites: Stanford, California; Minneapolis, Minnesota; Hawthorne, New York · 16 sites in all
- Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive ImpairmentPivotal-lookingActive, not recruiting
TakedaTakeda (TAK)
NCT06031259 · 6 participants · Start Mar 5, 2024 · Primary completion Jan 1, 2029
Drug: Idursulfase-IT; Elaprase · For: Hunter Syndrome
Sites: Calgary, Canada; Vancouver, Canada; Toronto, Canada · 4 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.